CXCL8 and melanoma: In a retrospective analysis, an early increase in serum levels of IL-8 predicted poor outcome in advanced NSCLC and melanoma patients treated with ICI-targeted monoclonal antibodies (mAbs) (Sanmamed et al., 2017).